Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex Therapy
AZTEK EXT
Quality of Life Analysis of Prostate Cancer Patient's Therapy
1 other identifier
observational
1,646
1 country
20
Brief Summary
This is an open label, non-interventional quality of life analysis for Zoladex treated prostate cancer patients by investigator's questionnaire
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2008
Typical duration for all trials
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2008
CompletedFirst Submitted
Initial submission to the registry
June 5, 2008
CompletedFirst Posted
Study publicly available on registry
June 6, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2010
CompletedDecember 10, 2010
December 1, 2010
2.1 years
June 5, 2008
December 9, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Elements of a general and three disease-specific investigator questionnaire
Quarterly (plus or minus 3 days )
Secondary Outcomes (1)
Investigator Assessment Report
Yearly (plus or minus 1 week )
Eligibility Criteria
Early or locally-advanced prostate cancer patients on androgen deprivation therapy
You may qualify if:
- Provision of informed consent
- Early or locally-advanced prostate cancer patients on androgen deprivation therapy
- Investigators are requested to recruit patients only with at least 1 month prior Zoladex treatment.
You may not qualify if:
- Allergy to substance of medication
- Prostate cancer patients with advanced disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (20)
Research Site
Baja, Hungary
Research Site
Békés, Hungary
Research Site
Békéscsaba, Hungary
Research Site
Budapest, Hungary
Research Site
Cegléd, Hungary
Research Site
Dunaújváros, Hungary
Research Site
Érd, Hungary
Research Site
Győr, Hungary
Research Site
Gyula, Hungary
Research Site
Kiskunhalas, Hungary
Research Site
Nagykőrös, Hungary
Research Site
Nyíregyháza, Hungary
Research Site
Pécs, Hungary
Research Site
Sopron, Hungary
Research Site
Szeged, Hungary
Research Site
Szentendre, Hungary
Research Site
Székesfehérvár, Hungary
Research Site
Tatabánya, Hungary
Research Site
Vác, Hungary
Research Site
Zalaegerszeg, Hungary
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Péter Tenke, M.D.
"Jahn Ferenc" City Hospital Budapest
- STUDY DIRECTOR
Csaba Csongvai
AstraZeneca Hungary
- STUDY CHAIR
Éva Gulyás
AstraZeneca Hungary
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
June 5, 2008
First Posted
June 6, 2008
Study Start
June 1, 2008
Primary Completion
July 1, 2010
Study Completion
September 1, 2010
Last Updated
December 10, 2010
Record last verified: 2010-12